Details for New Drug Application (NDA): 219972
The generic ingredient in HYRNUO is sevabertinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sevabertinib profile page.
Summary for 219972
| Tradename: | HYRNUO |
| Applicant: | Bayer Healthcare |
| Ingredient: | sevabertinib |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219972
Generic Entry Date for 219972*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 219972
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HYRNUO | sevabertinib | TABLET;ORAL | 219972 | NDA | Bayer HealthCare Pharmaceuticals Inc. | 50419-397 | 50419-397-01 | 120 TABLET, FILM COATED in 1 BOTTLE (50419-397-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Nov 19, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Nov 19, 2030 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 10,428,063 | Patent Expiration: | Oct 10, 2035 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | 12,679,836 | Patent Expiration: | Nov 14, 2043 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE HER2 (ERBB2) TYROSINE KINASE DOMAIN (TKD) ACTIVATING MUTATIONS AND WHO HAVE RECEIVED A PRIOR SYSTEMIC THERAPY | ||||||||
Complete Access Available with Subscription
